AU3695589A - Hybrid proteins - Google Patents

Hybrid proteins

Info

Publication number
AU3695589A
AU3695589A AU36955/89A AU3695589A AU3695589A AU 3695589 A AU3695589 A AU 3695589A AU 36955/89 A AU36955/89 A AU 36955/89A AU 3695589 A AU3695589 A AU 3695589A AU 3695589 A AU3695589 A AU 3695589A
Authority
AU
Australia
Prior art keywords
plasminogen activator
domain
hybrid
hybrid plasminogen
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU36955/89A
Other languages
English (en)
Inventor
John Spencer Emtage
Timothy John Roy Harris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Celltech Ltd
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888813113A external-priority patent/GB8813113D0/en
Priority claimed from GB888825330A external-priority patent/GB8825330D0/en
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Publication of AU3695589A publication Critical patent/AU3695589A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Amplifiers (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU36955/89A 1988-06-03 1989-06-02 Hybrid proteins Abandoned AU3695589A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB8813113 1988-06-03
GB888813113A GB8813113D0 (en) 1988-06-03 1988-06-03 Hybrid proteins
GB8825330 1988-10-28
GB888825330A GB8825330D0 (en) 1988-10-28 1988-10-28 Hybrid proteins

Publications (1)

Publication Number Publication Date
AU3695589A true AU3695589A (en) 1990-01-05

Family

ID=26293965

Family Applications (1)

Application Number Title Priority Date Filing Date
AU36955/89A Abandoned AU3695589A (en) 1988-06-03 1989-06-02 Hybrid proteins

Country Status (7)

Country Link
EP (1) EP0347078A1 (ko)
JP (1) JPH02504472A (ko)
KR (1) KR900702017A (ko)
AU (1) AU3695589A (ko)
DK (1) DK26590D0 (ko)
GB (1) GB2228007A (ko)
WO (1) WO1989012098A1 (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811265A (en) * 1988-08-19 1998-09-22 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5609869A (en) * 1988-08-19 1997-03-11 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
WO1991016353A1 (en) * 1990-04-23 1991-10-31 Corvas International N.V. Thrombus-specific antibody derivatives
CA2052283A1 (en) * 1990-09-27 1992-03-28 Edgar Haber Recombinant hybrid immunoglobulin molecules and method of use
JPH0576385A (ja) * 1990-12-18 1993-03-30 Takeda Chem Ind Ltd キメラ抗体およびその用途
US5808032A (en) * 1992-03-30 1998-09-15 Suntory Limited Anti-HBS antibody genes and expression plasmids therefor
US6984373B2 (en) 2000-12-23 2006-01-10 Dyax Corp. Fibrin binding moieties useful as imaging agents
AU2002248222B2 (en) * 2000-12-23 2006-04-27 Dyax Corp. Fibrin binding polypeptides useful inter alia in medical imaging processes
CA3120211A1 (en) * 2018-11-21 2020-05-28 Immunwork Inc. Polypeptide comprising an anti-fibrin antibody and a serine protease moiety of human tpa for treating pathological blood clots

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7282687A (en) * 1986-03-28 1987-10-20 Gabriel Alvarado-Urbina Protein analogues of tissue plasminogen activator
CA1339445C (en) * 1986-11-12 1997-09-09 The General Hospital Corporation Recombinant hybrid immunoglobulin molecules and method of use

Also Published As

Publication number Publication date
EP0347078A1 (en) 1989-12-20
DK26590A (da) 1990-02-01
JPH02504472A (ja) 1990-12-20
DK26590D0 (da) 1990-02-01
GB9001502D0 (en) 1990-04-04
KR900702017A (ko) 1990-12-05
WO1989012098A1 (en) 1989-12-14
GB2228007A (en) 1990-08-15

Similar Documents

Publication Publication Date Title
EP0271227B1 (en) Recombinant hybrid immunoglobulin molecules and their use
US5358932A (en) Hybrid protein C
CA1339546C (en) Recombinant hybrid immunogloblin molecules an method of use
EP0506821B1 (en) Hybrid protein c
EP0347078A1 (en) Hybrid proteins
WO1991016353A1 (en) Thrombus-specific antibody derivatives
AU624158B2 (en) Variants of plasminogen activators and processes for their production
Runge et al. Plasminogen activators. The old and the new.
US5811265A (en) Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
JP2008531023A (ja) 血栓溶解剤としての標的化プラスミノーゲンアクチベーター融合タンパク質
US5571708A (en) Thrombin-activatable plasminogen activator
AU615450B2 (en) Novel fibrinolytic enzymes
Holvoet et al. Biochemical characterization of single‐chain chimeric plasminogen activators consisting of a single‐chain Fv fragment of a fibrin‐specific antibody and single‐chain urokinase
EP0478366A2 (en) Recombinant hybrid immunoglobulin molecules and method of use
EP0275606A1 (en) Hybrid plasminogen activators with improved thrombolytic properties and drugs comprising these plasminogen activators
US5609869A (en) Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
WO2023195535A1 (ja) フィブリンに結合する抗体および当該抗体を含むフィブリン溶解性タンパク質および当該タンパク質を含む医薬製剤
NO900470L (no) Hybride proteiner.
EP0491351A2 (en) Chimeric antibodies and their use
JPH04346785A (ja) キメラプラスミノーゲンアクチベーター
Collen et al. K1K2Pu, a recombinant t-PA/u-PA Chimera with increased thrombolytic potency, consisting of amino acids 1 to 3 and 87 to 274 of human tissue-type plasminogen activator (t-PA) and amino acids 138 to 411 of human single chain urokinase-type plasminogen activator (scu-PA). Purification in centigram quantities and conditioning for use in man
US6682733B1 (en) Fibrinolytic enzymes
JPH04503450A (ja) 組換えハイブリッド免疫グロブリン分子および使用方法
WO1988000242A1 (en) Recombinant human tissue plasminogen activator composition
JPH07143877A (ja) 新規なｔ−ＰＡ類似体